

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT001	11/17/14	Email from Vergnano to Brown re update on liabilities	AFFF-MDL-EID-FT-00156187	AFFF-MDL-EID-FT-00156188
DFT002	6/5/15	June Houlihan Lokey Solvency Opinion Letter and Deck	AFFF-MDL-EID-FT-00096942	AFFF-MDL-EID-FT-00096997
DFT003	6/5/15	Letter from Houlihan Lokey to Chemours Company and DuPont re Separation Agreement	AFFF-MDL-EID-FT-00096942	AFFF-MDL-EID-FT-00096947
DFT004	6/5/15	Houlihan Lokey Final Spin Projections Deck	AFFF-MDL-HLokey00035927	AFFF-MDL-HLokey00035973
DFT005	6/4/15	Mark Newman Certificate to Houlihan Lokey re Financial Statements and Projections	AFFF-MDL-EID-FT-00097072	AFFF-MDL-EID-FT-00097085
DFT006	5/7/15	Sheryl Telford Backup Certificate to the Certificate to Houlihan Lokey	AFFF-MDL-EID-FT-00097086	AFFF-MDL-EID-FT-00097088
DFT007	5/7/15	Julie Mazza Backup Certificate to the Certificate to Houlihan Lokey	AFFF-MDL-EID-FT-00097014	AFFF-MDL-EID-FT-00097017
DFT008	5/7/15	Phillip Jones Backup Certificate to the Certificate to Houlihan Lokey	AFFF-MDL-EID-FT-00176470	AFFF-MDL-EID-FT-00176482
DFT009	5/7/15	Stephen Rahaim Backup Certificate to the Certificate to Houlihan Lokey	AFFF-MDL-EID-FT-00097012	AFFF-MDL-EID-FT-00097013
DFT010	7/21/15	Deloitte Deck re The Chemours Company - Contingent Liabilities	AFFF-MDL-EID-FT-00123352	AFFF-MDL-EID-FT-00123397
DFT011	8/1/13	Email from Esterling to Fischer, Strzelecki, West, Zelac, Giannantonio re David's Final presentation to the BOD attaching	AFFF-MDL-EID-FT-00022538	AFFF-MDL-EID-FT-00022594
DFT012	9/1/13	Performance Chemicals Strategic Assessment Update BOD deck	AFFF-MDL-EID-FT-00011513	AFFF-MDL-EID-FT-00011533
DFT013	10/16/13	Memo to Board of Directors from Ellen Kullman re Project Viking attaching BOD materials	AFFF-MDL-EID-FT-00011258	AFFF-MDL-EID-FT-00011453
DFT014	10/23/13	DuPont BOD Minutes	AFFF-MDL-EID-FT-00210242	AFFF-MDL-EID-FT-00210257
DFT015	10/24/13	Performance Chemicals strategic assessment BOD deck	AFFF-MDL-EID-FT-00012663	AFFF-MDL-EID-FT-00012725
DFT016	12/3/13	DuPont BOD Minutes	AFFF-MDL-EID-FT-00012490	AFFF-MDL-EID-FT-00012510
DFT017	3/1/14	Project Beta Update BOD deck	AFFF-MDL-EID-FT-00011462	AFFF-MDL-EID-FT-00011474

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT018	4/1/14	Project Beta Update BOD deck	AFFF-MDL-EID-FT-00012511	AFFF-MDL-EID-FT-00012529
DFT019	4/22/14	DuPont BOD Minutes	AFFF-MDL-EID-FT-00010629	AFFF-MDL-EID-FT-00010641
DFT020	10/22/14	Performance Chemicals Capital Structure Recommendation BOD deck	AFFF-MDL-EID-FT-00221525	AFFF-MDL-EID-FT-00221544
DFT021	11/18/14	DuPont BOD Minutes	AFFF-MDL-EID-FT-00010525	AFFF-MDL-EID-FT-00010526
DFT022	12/1/14	Email from Heffernan to Snell attaching final Dec 2014 BOD deck	NJ-CHE-FT2-239670	NJ-CHE-FT2-239678
DFT023	12/2/14	DuPont BOD Minutes	AFFF-MDL-EID-FT-00210086	AFFF-MDL-EID-FT-00210100
DFT024	12/3/14	Performance Chemicals Capital Structure Update by Grier BOD deck	AFFF-MDL-EID-FT-00009843	AFFF-MDL-EID-FT-00009850
DFT025	12/3/14	Performance Chemicals Business Outlook Vergnano BOD deck	AFFF-MDL-EID-FT-00008634	AFFF-MDL-EID-FT-00008646
DFT026	1/25/15	DuPont BOD Minutes	AFFF-MDL-EID-FT-00210239	AFFF-MDL-EID-FT-00210241
DFT027	2/10/15	Chemour Compoany RAS Financing Scenarios slide deck	AFFF-MDL-EID-FT-00010322	AFFF-MDL-EID-FT-00010338
DFT028	3/2/15	DuPont BOD Minutes	AFFF-MDL-EID-FT-00210158	AFFF-MDL-EID-FT-00210182
DFT029	3/2/15	Goldman Sachs and Evercore Performance Chemicals Alternative Transaction Process BOD deck	EVER-AFFF00018529	EVER-AFFF00018529
DFT030	3/3/15	Chemours Business Outlook Update, Capital Structure & Financing Plans deck	AFFF-MDL-EID-FT-00012543	AFFF-MDL-EID-FT-00012578
DFT031	5/11/15	Chemours BOD minutes	NJ-CHE-FT2-283479	NJ-CHE-FT2-283480
DFT032	5/11/15	DuPont BOD Minutes	AFFF-MDL-EID-FT-00010704	AFFF-MDL-EID-FT-00010711
DFT033	6/5/15	DuPont BOD Minutes	AFFF-MDL-EID-FT-00210140	AFFF-MDL-EID-FT-00210157
DFT034	6/5/15	June 5, 2015 BOD Materials	AFFF-MDL-EID-FT-00221023	AFFF-MDL-EID-FT-00221489
DFT035	6/5/15	Chemours Capital Structure Update BOD deck	NJ-CHE-FT2-258716	NJ-CHE-FT2-258731
DFT036	6/9/15	Chemours BOD minutes	NJ-CHE-FT2-282924	NJ-CHE-FT2-282938

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT037	6/11/15	Chemours May Financial Package Chemours Executive Team Slide Deck	NJ-CHE-FT2-051491	NJ-CHE-FT2-051523
DFT038	12/1/15	DuPont BOD Minutes	AFFF-MDL-EID-FT-00210116	AFFF-MDL-EID-FT-00210125
DFT039	1/15/14	Email from Grier to Kane re Chemours indemnification	AFFF-MDL-EID-FT-00017042	AFFF-MDL-EID-FT-00017043
DFT040	10/22/14	DuPont BOD Minutes	AFFF-MDL-EID-FT-00210198	AFFF-MDL-EID-FT-00210213
DFT041	6/22/15	Email from Dekker to Millet and McHugh re Bloomberg Story on Chemours' Liability	NJ-CHE-FT2-159663	NJ-CHE-FT2-159670
DFT042	3/8/17	Harris letter to Engel re Chamber Works ISRA - Spill Act	NJDEP-DPNT-CW02349660	NJDEP-DPNT-CW02349662
DFT043	3/12/18	Engel email re Chamer Works	NJDEP-DPNT-CW02360007	NJDEP-DPNT-CW02360008
DFT044	9/5/14	Credit Suisse Materials for discussion deck	AFFF-MDL-EID-FT-00097622	AFFF-MDL-EID-FT-00097641
DFT045	1/27/15	Email from Kullman to Megginson re 4th Quarter Earnings News Release Final attaching news release	AFFF-MDL-EID-FT-00089854	AFFF-MDL-EID-FT-00089871
DFT046	10/3/15	Email from Giancristoforo to Friedman, Johnson, et al re Final Preannounce Documents attaching zip	AFFF-MDL-EID-FT-00015704	AFFF-MDL-EID-FT-00015752
DFT047	1/15/13	Project Beta: Introduction deck	NJ-CHE-FT2-255559	NJ-CHE-FT2-255576
DFT048	11/5/13	Project Beta Update - Update with Ellen deck	NJ-CHE-FT2-258884	NJ-CHE-FT2-258900
DFT049	11/22/13	Project Beta Kick-Off Meeting slide deck	AFFF-MDL-EID-FT-00006684	AFFF-MDL-EID-FT-00006785
DFT050	7/21/14	Project Beta Update BOD deck	AFFF-MDL-EID-FT-00010779	AFFF-MDL-EID-FT-00010790
DFT051	9/9/14	Email from Zelac to Vergnano and Giannantonio re Tronox env liabilities attaching Tronox chart	AFFF-MDL-EID-FT-00156185	AFFF-MDL-EID-FT-00156186
DFT052	10/4/14	Email from Ward to Ward re Tronox Summary attaching chart	AFFF-MDL-EID-FT-00217589	AFFF-MDL-EID-FT-00217591
DFT053	10/30/14	Presentation re Project Beta Agreements Principles around sharing	NJ-CHE-FT2-277187	NJ-CHE-FT2-277199
DFT054	2/2/15	Email from Guest to Shelton re Wachtell meeting	AFFF-MDL-EID-FT-00208308	AFFF-MDL-EID-FT-00208309
DFT055	2/27/15	Email from Wang re Chemours questions and requests on MSA attaching questions	AFFF-MDL-EID-FT-00206290	AFFF-MDL-EID-FT-00206298
DFT056	3/4/15	Email from Vergnano to Shelton re conversation with Stacy Fox	AFFF-MDL-EID-FT-00205435	AFFF-MDL-CHE-FT-00205435

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT057	3/4/15	Email from Shelton to Fox re Follow up to our conversation	AFFF-MDL-EID-FT-00205380	AFFF-MDL-EID-FT-00205380
DFT058	3/10/15	Email from Wang to Shelton re Chemours questions or requests re MSA attaching document	AFFF-MDL-EID-FT-00205020	AFFF-MDL-EID-FT-00205026
DFT059	4/5/15	Email from Shelton to Guest re quick question re non competes	AFFF-MDL-EID-FT-00208310	AFFF-MDL-EID-FT-00208310
DFT060	4/7/15	Email from West to Van Dyke and Wang re Wednesday Meeting - Agreement Update	AFFF-MDL-EID-FT-00098323	AFFF-MDL-EID-FT-00098325
DFT061	5/21/15	Email from Ward to De Rose, Schade, Teigman re Chemours Spinoff	AFFF-MDL-EID-FT-00159532	AFFF-MDL-EID-FT-00159532
DFT062	6/25/15	Email from Bellezza to Newman and Vergnano re Draft Q&A attaching Potential Additional Questions from Trian	NJ-CHE-FT2-051617	NJ-CHE-FT2-051621
DFT063	00/00/00	Timeline	n/a	n/a
DFT064	9/19/13	Email from Ralhan to Wang, et al. re Spin-co Assessment materials attaching Goldman Sachs deck	AFFF-MDL-EID-FT-00091862	AFFF-MDL-EID-FT-00091863_0020
DFT065	9/19/13	Email from Wang to Ralhan, et al. re Spin-co Assessment materials attaching Evercore deck	AFFF-MDL-EID-FT-00091864	AFFF-MDL-EID-FT-00091865_0052
DFT066	10/2/13	Email from Bills to Vergnano re Spin-Co Assessment Materials attaching Evercore decks	AFFF-MDL-EID-FT-00022043	AFFF-MDL-EID-FT-00022043
DFT067	10/10/13	Email from de la Chevallierie to Giannantonio and Zelac re Beta-Board Presentation - Latest Draft attaching presentation	AFFF-MDL-EID-FT-00091858	AFFF-MDL-EID-FT-00091859_0025
DFT068	10/22/13	Email from de la Chevallierie to Zelac re Project Beta - Final Bank Presentation for Board Meeting attaching Goldman Sachs and Evercore deck	AFFF-MDL-EID-FT-00101647	AFFF-MDL-EID-FT-00101663
DFT069	11/6/13	Email from Schaible to Giannantonio re Evercore's Work - Past, Present and Future attaching summary of Evercore work and spinoff process outline	AFFF-MDL-EID-FT-00102032	AFFF-MDL-EID-FT-00102049
DFT070	1/1/14	Apollo slide deck re January 2015 Discussion Materials	GS-AFFF0000167	GS-AFFF0000177
DFT071	1/14/14	Goldman Sachs and Evercore slide deck re Project Beta, Review of Updated Tronox Indication of Interest	GS-AFFF0006595	GS-AFFF0006620
DFT072	8/6/14	Email from Zelac to Giannantonio re Beta - Spin/Split Evaluation attaching Goldman Sachs Evercore deck re spin vs split	AFFF-MDL-EID-FT-00018583	AFFF-MDL-EID-FT-00018618

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT073	8/22/14	Email from Zelac to Todd, Ralhan, de la Chevallierie, Schaible, Bryson, Mensch re Spin - Split review attaching evaluation decks	AFFF-MDL-EID-FT-00018310	AFFF-MDL-EID-FT-00018343
DFT074	8/28/14	Email from Lodge to Grier attaching draft Credit Suisse spin proceeds deck and draft management & audit committee deck	AFFF-MDL-EID-FT-00015391	AFFF-MDL-EID-FT-00015475
DFT075	9/5/14	Email from Cutler to Fanandakis, Grier and Kane attaching final JPM Capital Structure Considerations deck for audit committee meeting	AFFF-MDL-EID-FT-00001178	AFFF-MDL-EID-FT-00001201
DFT076	2/2/15	Zelac email to Wang, Giannantonio, Bills, et al., re sponsored spin discussion additional discussion topic attaching Apollo offer presentation	AFFF-MDL-EID-FT-00091680	AFFF-MDL-EID-FT-00091681_0006
DFT077	2/10/15	Email from Heffernan to West, Ward and Zelac re Chemours - Moody's RAS financing scenarios attaching slide deck	AFFF-MDL-EID-FT-00073506	AFFF-MDL-EID-FT-00073524
DFT078	3/19/15	Email from Bills to Giannantonio re Axiall's Revised RMT Proposal for Consideration	AFFF-MDL-EID-FT-00092065	AFFF-MDL-EID-FT-00092072
DFT079	3/19/15	Email from Giannantonio to Fanandakis, Kullman re Assessment of Axiall's Chemours Proposal attaching Evercore/GS deck	AFFF-MDL-EID-FT-00023379	AFFF-MDL-EID-FT-00023386
DFT080	3/25/15	Email from Zelac to Giannantonio and Bills re Beta - Updated Transaction Review attaching Axiall analysis	AFFF-MDL-EID-FT-00022432	AFFF-MDL-EID-FT-00022440
DFT081	4/9/15	KPMG deck re Chemours Balance Sheet	AFFF-MDL-EID-FT-00097799	AFFF-MDL-EID-FT-00097842
DFT082	4/12/15	Email from Fanandakis to Kullman re Assessment of Axiall Proposal attaching Evercore and Goldman Sachs presentation	AFFF-MDL-EID-FT-00155266	AFFF-MDL-EID-FT-00155283
DFT083	4/20/15	Email from Heffernan to Wang and Bryson attaching Chemours Dividend presentation	AFFF-MDL-EID-FT-00021765	AFFF-MDL-EID-FT-00021773
DFT084	4/27/15	Email from Heffernan to Zelac to Chemours Credit Rating attaching ratings	AFFF-MDL-EID-FT-00080460	AFFF-MDL-EID-FT-00080474
DFT085	6/25/15	Email from Grier to Heffernan attaching Goldman Sachs summary of Chemours broker valuation and commentary	AFFF-MDL-EID-FT-00097988	AFFF-MDL-EID-FT-00097990
DFT086	11/22/13	Project Beta Kick-Off Meeting slide deck	AFFF-MDL-EID-FT-00019728	AFFF-MDL-EID-FT-00019829
DFT087	4/29/14	Engagement Agreement between Houlihan Lokey Financial Advisors and E. I. du Pont de Nemours and Company	AFFF-MDL-HLokey00000966	AFFF-MDL-HLokey00000976
DFT088	8/1/14	Pond email to Zelac, Clampitt re Project Beta strategy documents	AFFF-MDL-EID-FT-00005457	AFFF-MDL-EID-FT-00005457

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT089	8/22/14	Email from Ward to Grier, Fox and West re BOD talking points on solvency opinion process attaching Project Beta Overview Solvency Opinions deck	AFFF-MDL-EID-FT-00205453	AFFF-MDL-EID-FT-00205456
DFT090	11/10/14	Calendar invite from Ward to Grier, Heffernan, et al., re Solvency Opinion Process kickoff meeting with Houlihan Lokey	AFFF-MDL-EID-FT-00123521	AFFF-MDL-EID-FT-00123521
DFT091	1/29/15	Email from Schade to Ward and Pond re Agenda for HL Feb. 3 meeting attaching meeting agenda with Newman and Vergnano	AFFF-MDL-EID-FT-00160674	AFFF-MDL-EID-FT-00160678
DFT092	2/1/15	Email from Ward to Rahaim and Mazza re Draft HL Materials attaching The Chemours Company Preliminary Discussion Materials for CARC	AFFF-MDL-EID-FT-00213242	n/a
DFT093	2/6/15	Email from Ward to Newman attaching Agenda for HL Feb 11th meeting	AFFF-MDL-EID-FT-00205954	AFFF-MDL-EID-FT-00205955
DFT094	2/17/15	Email from Nelson to Ward re HL follow-up	AFFF-MDL-EID-FT-00217097	AFFF-MDL-EID-FT-00217099
DFT095	2/17/15	Email from Heffernan to Ward re HL follow-up attaching Chemours model	AFFF-MDL-EID-FT-00087737	AFFF-MDL-EID-FT-00087739
DFT096	2/17/15	Email from Ward to Nelson re HL follow-up attaching Chemours model	AFFF-MDL-EID-FT-00217100	AFFF-MDL-EID-FT-00217102
DFT097	2/18/15	Email from Ward to Ward re Solvency Opinion Process Slides attaching Houlihan Lokey deck	AFFF-MDL-EID-FT-00217046	AFFF-MDL-EID-FT-00217096
DFT098	2/19/15	Email from Ward to Kling and Van Dyke re Houlihan Lokey materials attaching HL deck re overview of the opinion process	AFFF-MDL-EID-FT-00160571	AFFF-MDL-EID-FT-00160591
DFT099	2/23/15	Email from De Rose to Grier re Houlihan Board Presentation	AFFF-MDL-EID-FT-00016555	AFFF-MDL-EID-FT-00016568
DFT100	3/2/15	Email from Ward to De Rose and Schade attaching Beta Financing Board Slides	AFFF-MDL-EID-FT-00030974	AFFF-MDL-EID-FT-00030976
DFT101	4/8/15	Email from Whitticom to Lang, Heffernan re checking in	AFFF-MDL-EID-FT-00066330	AFFF-MDL-EID-FT-00066334
DFT102	4/23/15	Email from Teigman to Heffernan, Schade, Newman re Draft HL Materials Feedback attaching draft CARC materials	AFFF-MDL-EID-FT-00053060	AFFF-MDL-EID-FT-00053092
DFT103	5/1/15	Chemours Cyclicalality (CARC Only) deck	AFFF-MDL-HLokey00036063	AFFF-MDL-HLokey00036066
DFT104	5/5/15	DRAFT Chemours CARC Materials v8.pptx	AFFF-MDL-HLokey00024381	AFFF-MDL-HLokey00024500

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT105	5/7/15	Newman Certificate to Houlihan Lokey re Financial Statements and Projections	NJ-CHE-FT2-282939	NJ-CHE-FT2-282953
DFT106	5/11/15	May Houlihan Lokey Solvency Opinion Letter and Deck	AFFF-MDL-EID-FT-00097018	AFFF-MDL-EID-FT-00097071
DFT107	5/11/15	Houlihan Lokey preliminary discussion materials for CARC deck	AFFF-MDL-HLokey00024381	AFFF-MDL-HLokey00024500
DFT108	5/19/15	Calendar invite from Ward to Newman, Heffernan, West, et al. re Discussion with Houlihan Lokey on Chemours Model	AFFF-MDL-EID-FT-00150604	AFFF-MDL-EID-FT-00150604
DFT109	5/23/15	Email from Vergnano to Newman re 2015 Chemours Financial Overview	NJ-CHE-FT2-241671	NJ-CHE-FT2-241673
DFT110	5/28/15	Email from Heffernan to DeRose and Ward re Updated Model attaching Chemours model	AFFF-MDL-EID-FT-00077836	AFFF-MDL-EID-FT-00077837
DFT111	5/29/15	Houlihan Lokey letter to DuPont re bringdown opinion amendment to engagement agreement	AFFF-MDL-Hlokey00035732	AFFF-MDL-Hlokey00035733
DFT112	6/1/15	Fanadakis Certificate to Houlihan Lokey regarding Financial Statements and Projections	AFFF-MDL-HLokey00035774	AFFF-MDL-HLokey00035787
DFT113	6/1/15	Email from Ward to West re board charts	AFFF-MDL-EID-FT-00039380	AFFF-MDL-EID-FT-00039381
DFT114	5/6/19	Houlihan Lokey Letter re DowDuPont	AFFF-MDL-EID-FT-00201902	AFFF-MDL-EID-FT-00201906
DFT115	5/6/19	Houlihan Lokey Powerpoint re Corteva	AFFF-MDL-EID-FT-00201949	AFFF-MDL-EID-FT-00201993
DFT116	5/6/19	Houlihan Lokey Powerpoint re DowDuPont	AFFF-MDL-EID-FT-00201619	AFFF-MDL-EID-FT-00201660
DFT117	9/4/14	Email from Heffernan to Fanandakis and Grier attaching PChem Model Review Slides	AFFF-MDL-EID-FT-00143076	AFFF-MDL-EID-FT-00143094
DFT118	2/3/15	Native Excel - Project Beta Model	AFFF-MDL-EID-FT-00091738	AFFF-MDL-EID-FT-00010121
DFT119	3/31/15	Email from Heffernan to Newman re Chemours Covenant Analysis attaching model	AFFF-MDL-EID-FT-00084138	AFFF-MDL-EID-FT-00084139
DFT120	4/20/15	Native Excel - Copy of Chemours Dynamic Lender Model	AFFF-MDL-HLokey00024117	AFFF-MDL-HLokey00024117
DFT121	5/23/15	Email from Heffernan to Newman, Wood, Ralhan, Rastogi re LTM EBITDA attaching model spreadsheet and pdf	AFFF-MDL-EID-FT-00077990	AFFF-MDL-EID-FT-00077992



<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT122	5/25/15	Email from Wood to Heffernan re 2015 Chemours Financial Overview	AFFF-MDL-EID-FT-00039721	AFFF-MDL-EID-FT-00039726
DFT123	5/28/15	Email from Heffernan to Grier re Chemours Update attaching updated model	AFFF-MDL-EID-FT-00077792	AFFF-MDL-EID-FT-00077835
DFT124	5/31/15	Email chain re CFO certificate edits attaching Chemours model	NJ-CHE-FT2-272123	NJ-CHE-FT2-272129
DFT125	6/1/15	Email from Newman to Vergnano re Chemours HL model with base case and downside scenario	NJ-CHE-FT2-020822	NJ-CHE-FT2-020825
DFT126	6/4/15	Email from De Rose to Heffernan re updated model	AFFF-MDL-EID-FT-00039159	AFFF-MDL-EID-FT-00039161
DFT127	2/25/25	Models given to Houlihan Lokey, Native Format - excel	AFFF-MDL-EID-FT-00008375	AFFF-MDL-EID-FT-00008375
DFT128	12/17/05	US Senate Judiciary Committee Hearing re Recent Developments in Assessing Future Asbestos Claims under the Fair Act	DT00004998	DT00005285
DFT129	3/28/14	Email from Walker to Parikh re 1 of 4 emails attaching Mazza Request spreadsheet	DT00005505	DT00005510
DFT130	3/28/14	Email from Walker to Parikh re 2 of 4 emails attaching Titanium Technologies and Chemical Solutions & Fluoro spreadsheets	DT00005511	DT00005586
DFT131	3/28/14	Email from Walker to Parikh re 3 of 4 emails attaching Legal Request of FuPont spreadsheet	DT00005587	DT00005599
DFT132	3/28/14	Email from Walker to Parikh re 4 of 4 emails attaching PFOA litigation spend spreadsheet	DT00005600	DT00005604
DFT133	4/2/14	Gilford email to B. Walker, P. Parikh re Remington Case Historical Costs	DT00000101	DT00000113
DFT134	4/14/14	Email from Gilford to Parikh re DuPont Benzene Litigation Update attaching spreadsheet	DT00000142	DT00000152
DFT135	4/23/14	Engagement agreement between Skadden and Deloitte	DT00005630	DT00005635
DFT136	4/28/14	Meeting invite from Mazza to Ward, Wang, Pond, DeCarli, Miller, Mariani, VanDyke, Scrivani, Parikh, Trainor, Rees re Beta liabilities update	AFFF-MDL-EID-FT-00214605	AFFF-MDL-EIT-FT-00214605
DFT137	6/3/14	Email from Trainor to Mazza re Project Beta Overview Slides attaching Deloitte June deck	DT00000585	DT00000591
DFT138	10/6/14	Meeting invite from Olagues to Mazza, Gilford, Trainor, Parikh, Mariani re PFOA Update Conference Call	AFFF-MDL-EID-FT-00214596	AFFF-MDL-EID-FT-00214596



<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT139	10/24/14	Email from Gilford to Trainor and Parikh re DuPont C8 Personal Injury Litigation - Claims per Injury attaching report	DT00000183	DT00000190
DFT140	10/27/14	Email from Parikh to Gilford attaching case termination statistics	DT00006752	DT00006755
DFT141	10/27/14	Email from Parikh to Gilford attaching decision tree pdf, product liability disposition document and support zip	DT00006635	DT00006747
DFT142	10/31/14	Parikh email to Gilford attaching third of four zip files (3/4)	DT00001460	DT00002387
DFT143	10/31/14	Parikh email to L. Gilford, N. Moghaddam, K. Sclaes re Docs Relied Upon (4/4)	DT00001348	DT00001459
DFT144	10/31/14	Parikh email to L. Gilford, N. Moghaddam, K. Sclaes re Docs Relied Upon (2/4)	DT00002388	DT00003388
DFT145	10/31/14	Parikh email to L. Gilford, N. Moghaddam, K. Sclaes re Docs Relied Upon (1/4)	DT00003815	DT00005307
DFT146	11/11/14	Email from Gilford to Parikh and Trainor re edits to draft deck re Analysis of Fair Market Value of Certain Litigation Costs attaching draft deck	DT00010921	DT00010955
DFT147	11/12/14	Email from Parikh to Gilford attaching Deloitte November deck	DT00010956	DT00010964
DFT148	11/13/14	Gilford email to Parikh attaching Project Beta, Litigation Related Inputs to Solvency Opinion slide decks	DT00010975	DT00011023
DFT149	11/19/14	Meeting Invite from Slayton to Fox, Mazza, Brantley, Shelton, Gilford, Reilly re Meeting with Deloitte	AFFF-MDL-EID-FT-00205182	AFFF-MDL-EID-FT-00205182
DFT150	12/11/14	Email from Parikh to Gilford attaching Deloitte deck	DT00011063	DT00011082
DFT151	12/11/14	Shelton handwritten notes re Deloitte meeting	NJ-CHE-FT2-283643	NJ-CHE-FT2-283646
DFT152	1/23/15	Email from Pond to Mazza attaching Deloitte February deck	AFFF-MDL-EID-FT-00211923	AFFF-MDL-EID-FT-00211945
DFT153	2/2/15	Deloitte Contingent Liabilities February deck	AFFF-MDL-HLokey00011913	AFFF-MDL-HLokey00011928
DFT154	2/2/15	Email from Mazza to Fox re Houlihan Lokey meeting with Deloitte	AFFF-MDL-EID-FT-00215116	AFFF-MDL-EID-FT-00215116
DFT155	4/30/15	Email from Gilford to Parikh re request for updated personal injury chart for PFOA	DT00000312	DT00000314
DFT156	5/7/15	Email from Parikh to Gilford and Moghaddam attaching draft Deloitte analysis	DT00011283	DT00011328
DFT157	1/1/16	KCIC Industry Report - "Asbestos Litigation: 2016 Year in Review	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT158	6/25/24	Radiation Exposure Compensation Act overview from US Department of Justice	n/a	n/a
DFT159	00/00/00	Parikh email to L. Gilford, N. Moghaddam, K. Sclaes re Docs Relied Upon (3/4)	DT00001460	DT00002387
DFT160	00/00/13	Gilford email to E. Trainor, P. Parikh re uPont C8 Personal injury litigation claims per injury	DT00000183	DT00000190
DFT161	10/14/14	Email from Rees to Heffernan re updated charts attaching Oct 2014 BOD Presentation re Pchem environmental and litigation	AFFF-MDL-EID-FT-00205457	AFFF-MDL-EID-FT-00205464
DFT162	10/15/14	Email from Ward van Dyke re Final Slides used with Mark attaching deck re review of environmental and litigation contingencies	AFFF-MDL-EID-FT-00215743	AFFF-MDL-EID-FT-00215765
DFT163	2/7/15	Email from Grier to Lodge re Moody's Chemours RAS Question	AFFF-MDL-EID-FT-00017402	AFFF-MDL-EID-FT-00017403
DFT164	10/8/15	Jefferies analyst report re CC "PFOA Litigation Update: First Loss"	n/a	n/a
DFT165	7/10/16	Email from Newman to Tom re Debtwire article	NJ-CHE-FT2-051857	NJ-CHE-FT2-051859
DFT166	1/17/17	Email from Claps to Newman and Bellezza re CC - PFOA estimate remains at \$550M as new trial begins today article	NJ-CHE-FT2-060422	NJ-CHE-FT2-060425
DFT167	1/31/14	Email from Leeds to Telford, Dewson, Ei, Lukas and Shoemaker re Discussion Monday - Environmental Liability Transference attaching draft plan	NJ-CHE-FT2-227200	NJ-CHE-FT2-227204
DFT168	10/17/14	Email from Vergnano to Snell re PChem Remediation Sites	NJ-CHE-FT2-239734	NJ-CHE-FT2-239734
DFT169	12/31/14	Native Excel - SPGI CRG Example	AFFF-MDL-EID-FT-00010121	AFFF-MDL-EID-FT-00010121
DFT170	1/19/15	Email from Ward to King, Van Dyke, Scrivani, and Gilford re HL due diligence attaching Environmental Remediation Obligations deck	AFFF-MDL-EID-FT-00217133	AFFF-MDL-EID-FT-00217139
DFT171	4/7/15	Email from Telford to Shelton re 2014 year end reserve for each site	AFFF-MDL-EID-FT-00215126	AFFF-MDL-EID-FT-00215130
DFT172	4/29/15	Email from Telford to Rahaim re Solvency Opinion attaching CRG spreadsheet	NJ-CHE-FT2-042869	NJ-CHE-FT2-042870
DFT173	5/20/15	Native Excel - CRG High End vs Low End Estimates	AFFF-MDL-EID-FT-00010524	AFFF-MDL-EID-FT-00010524
DFT174	9/19/15	Email from Telford to Liu re CRG attaching CRG documents	NJ-CHE-FT2-105853	NJ-CHE-FT2-105913
DFT175	11/1/23	Print out of Liabilities, 410 Asset Retirement and Environmental Obligations, 30 Environmental Obligations	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT176	00/00/00	PwC - Operating, maintenance and monitoring guidance document for remediation range estimates	PwC-AFFF000035	PwC-AFFF000036
DFT177	00/00/13	High End Cost Estimates Charts	OAG-Chem-327991	OAG-Chem-327991
DFT178	00/00/14	Native Excel - 2014 Q3 CRG High End vs. Low End Remediation Estimates	AFFF-MDL-EID-FT-00010345	AFFF-MDL-EID-FT-00010345
DFT179	1/1/15	Chemours Financial Review 2Q 2015 Actual and FY 2015 Outlook deck	NJ-CHE-FT2-052318	NJ-CHE-FT2-052334
DFT180	1/29/15	Email from Hefferman to Wood and Ralhan re PChem Operating Reviews attaching slide deck	AFFF-MDL-EID-FT-00074489	AFFF-MDL-EID-FT-00074523
DFT181	3/4/15	Email from Vergnano to Fanandakis and Newman re Chemours Bond Financing	NJ-CHE-FT2-258469	NJ-CHE-FT2-258469
DFT182	4/21/15	Email from Anos to Grier, Meneely, Newman, Ralhan re DB Commitment letter attaching Deutsche Bank letter	AFFF-MDL-EID-FT-00016509	AFFF-MDL-EID-FT-00016512
DFT183	4/22/15	Chemours Lender Presentation	NJ-CHE-FT2-236069	NJ-CHE-FT2-236071
DFT184	5/3/15	Email from Lodge to Grier re heads up	AFFF-MDL-EID-FT-00144651	AFFF-MDL-EID-FT-00144652
DFT185	5/11/15	Email from Zelac to Bryson, Wang attaching Introduction to The Chemours Company deck presented by Mark Vergnano	AFFF-MDL-EID-FT-00099209	AFFF-MDL-EID-FT-00099266
DFT186	5/12/15	Email from Meneely to Grier re Financing Closed/Net Proceeds Received - Proceeds Invested attaching investment strategy	AFFF-MDL-EID-FT-00142502	AFFF-MDL-EID-FT-00142509
DFT187	5/19/15	Email from Zelac to Ward attaching draft Chemours equity roadshow deck	AFFF-MDL-EID-FT-00091411	AFFF-MDL-EID-FT-00091412_0028
DFT188	5/23/15	Email from Snell to Wood re 2015 Chemours Financial Overview	NJ-CHE-FT2-242785	NJ-CHE-FT2-242786
DFT189	6/1/15	The Chemours Company Investor Presentation slide deck	NJ-CHE-FT2-159408	NJ-CHE-FT2-159432
DFT190	6/1/15	Email from West to Grier re Board charts	AFFF-MDL-EID-FT-00144463	AFFF-MDL-EID-FT-00144464
DFT191	6/1/15	Email from Vergnano to Kullman re note to board re Fresh Start program	NJ-CHE-FT2-260894	NJ-CHE-FT2-260894
DFT192	6/1/15	Chemours Company Investor Presentation	NJ-CHE-FT2-020939	NJ-CHE-FT2-020963
DFT193	6/2/15	Email from Grier to West re Chemours Liquidity Analysis	AFFF-MDL-EID-FT-00183585	AFFF-MDL-EID-FT-00183591

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT194	6/2/15	Email from Newman to Grier, Heffernan, Fanandakis, Vergnano, Shelton, Ralhan, Wood re Chemours Liquidity Analysis attaching Chemours Outlook deck	AFFF-MDL-EID-FT-00202508	AFFF-MDL-EID-FT-00202514
DFT195	6/2/15	Email from Zelac to Grier attaching draft Chemours equity roadshow deck	AFFF-MDL-EID-FT-00144255	AFFF-MDL-EID-FT-00144278
DFT196	6/3/15	Email from Grier to Newman re Chemours Liquidity Analysis	AFFF-MDL-EID-FT-00145242	AFFF-MDL-EID-FT-00145244
DFT197	6/3/15	Email from Grier to Fanandakis attaching presentation re Chemours Liquidity for discussion between Grier, West and Heffernan	AFFF-MDL-EID-FT-00017248	AFFF-MDL-EID-FT-00017261
DFT198	6/3/15	Email from King to Van Dyke, West, and Ward re CFO Certificate	AFFF-MDL-EID-FT-00214340	AFFF-MDL-EID-FT-00214341
DFT199	6/3/15	Email from Newman to Ralhan re Chemours Liquidity Analysis	NJ-CHE-FT2-020869	NJ-CHE-FT2-020871
DFT200	6/10/15	Email from Leeds to Lee re May CET Financial Deck attaching deck	NJ-CHE-FT2-051490	NJ-CHE-FT2-051523
DFT201	6/10/15	Email from Ward to Kling attaching draft Chemours equity roadshow deck	AFFF-MDL-EID-FT-00215521	AFFF-MDL-EID-FT-00215546
DFT202	8/3/15	Email from Kane to Giannantonio attaching DD RAS RES Presentation Jan 2015 master deck	AFFF-MDL-EID-FT-00022371	AFFF-MDL-EID-FT-00022398
DFT203	12/21/15	Email from Fanandakis to Vergnano re follow up to your text message	NJ-CHE-FT2-258851	NJ-CHE-FT2-258853
DFT204	12/23/15	Email from Fox to Vaske, Van Dyke, West, Fanandakis re Chemours Proposal, attaching proposal	AFFF-MDL-EID-FT-00090497	AFFF-MDL-EID-FT-00090499_0002
DFT205	1/17/16	Email from Fox to West re 1/18 call agenda	AFFF-MDL-EID-FT-00217691	AFFF-MDL-EID-FT-00217692
DFT206	1/29/16	Email from Newlin to Vergnano re Agreement with DuPont	NJ-CHE-FT2-023942	NJ-CHE-FT2-023943
DFT207	2/1/16	Letter Agreement between DuPont and Chemours re liquidity assistance	NJ-CHE-FT2-048595	NJ-CHE-FT2-048600
DFT208	5/18/16	Email from Vergnano to Vergnano attaching Vergnano change story	NJ-CHE-FT2-026246	NJ-CHE-FT2-026248
DFT209	7/12/16	Letter from Fox to Shelton re Indemnification	AFFF-MDL-EID-FT-00207069	AFFF-MDL-EID-FT-00207071
DFT210	2/13/17	Letter from Shelton and Vergnano to Chemours Colleagues re Ohio MDL settlement	NJ-CHE-FT2-238344	NJ-CHE-FT2-238344
DFT211	11/3/17	DuPont Global Public Affairs Pulse email	AFFF-MDL-EID-FT-00029857	AFFF-MDL-EID-FT-00029859

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT212	7/23/13	Oppenheimer analyst report re DD "Strategic Review for Perf. Chemicals; Guidance Back-End Loaded"	n/a	n/a
DFT213	7/23/13	Barclays analyst report re DD "Performance Chemicals Strategic Alternatives Conversation Trump Earnings"	n/a	n/a
DFT214	10/25/13	Credit Suisse analyst report re DD "Limited Additional Valuation Creation on Performance Chemical Spin"	n/a	n/a
DFT215	10/7/14	UBS analyst report re DD "Green Chemistry: Beginning of End...?"	n/a	n/a
DFT216	10/28/14	Deutsche Bank analyst report re DD "Q3 Beats on Taxes. Q4 Guidance \$0.01 Above Consensus"	n/a	n/a
DFT217	3/16/15	Bank of America analyst report re DD "Moving to Underperform; trimming numbers on FX, Ag"	n/a	n/a
DFT218	4/21/15	Bank of America analyst report re DD "Maintain estimates and PO as proxy contest intensifies"	n/a	n/a
DFT219	4/24/15	S&P Ratings, "Chemours Co. Assigned 'BB' Corporate Credit Rating, Outlook Stable; Debt Ratings Assigned"	n/a	n/a
DFT220	4/27/15	Bank of America analyst report re DD "ISS Endorses two Trian board nominees including Peltz"	n/a	n/a
DFT221	4/30/15	S&P Ratings, "The Chemours Company's Recovery Rating Profile"	n/a	n/a
DFT222	5/7/15	JPM Model, Native format - excel	JPM-AFFF-00005445	JPM-AFFF-00005445
DFT223	6/10/15	UBS analyst report re DD "CC Spin from DD A-Ok'd; PF Models Updated"	AFFF-MDL-EID-FT-00145083	AFFF-MDL-EID-FT-00145096
DFT224	6/18/15	RF Lafterty analyst report "DD/CC looks like a high risk play with legitimate concerns over dividend sustainability"	AFFF-MDL-EID-FT-00145061	AFFF-MDL-EID-FT-00145069
DFT225	6/18/15	PiperJaffray analyst report re DD "Our Take on Core DuPont Earnings Power Post-Spin; Maintain Neutral"	NJ-CHE-FT2-159400	NJ-CHE-FT2-159407
DFT226	6/19/15	UBS analyst report re DD "Dividend gap or info gap?"	NJ-CHE-FT2-159368	NJ-CHE-FT2-159373
DFT227	6/19/15	Morgan Stanley analyst report "Chemours / DuPont Spin-Off"	NJ-CHE-FT2-159374	NJ-CHE-FT2-159499
DFT228	6/22/15	Credit Suisse analyst report re DD "If You Want Your Dividend, You're Going to Get to Keep Your Dividend...Maybe Not"	AFFF-MDL-EID-FT-00145003	AFFF-MDL-EID-FT-00145011
DFT229	6/22/15	Jefferies analyst report re CC "A Severe Case of Asterism. Initiate with Buy."	AFFF-MDL-EID-FT-00145012	AFFF-MDL-EID-FT-00145034
DFT230	6/22/15	Jefferies analyst report re DD "Chemours Gone, a New Checklist"	AFFF-MDL-EID-FT-00145076	AFFF-MDL-EID-FT-00145082

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT231	6/23/15	Jefferies analyst report re DD "Who Wants What?"	AFFF-MDL-EID-FT-00100478	AFFF-MDL-EID-FT-00100485
DFT232	6/24/15	JP Morgan analyst report re CC "We Initiate Coverage with an Underweight Rating"	n/a	n/a
DFT233	6/24/15	JP Morgan analyst report re DD "Sans Chemours"	n/a	n/a
DFT234	6/25/15	Email from Newman to Malmberg re Chemours Update Call attaching Goldman Sachs summary of Chemours broker valuation and commentary	NJ-CHE-FT2-051612	NJ-CHE-FT2-051615
DFT235	7/1/15	Jefferies analyst report re CC "10 Debates"	n/a	n/a
DFT236	7/2/15	RBC Capital Markets analyst report re DD "Lowering Estimates and Target for Chemours Spin"	n/a	n/a
DFT237	7/6/15	Barclays analyst report re CC "Deep Value Beats Weak Fundamentals; Initiating with OW rating"	n/a	n/a
DFT238	7/6/15	UBS analyst report re CC "Leader in Opaqueness - how bright is the future?"	n/a	n/a
DFT239	7/27/15	SIG Susquehanna analyst report re CC "Initiating Coverage with Neutral Rating"	n/a	n/a
DFT240	8/7/15	Barclays analyst report re CC "The Bad, The Good, The Beautiful"	n/a	n/a
DFT241	8/7/15	JP Morgan analyst report re CC "Raising from Underweight to	n/a	n/a
DFT242	8/12/15	SIG Susquehanna analyst report re CC "Accelerating Cost Reductions to Offset Weak TiO2 Outlook"	n/a	n/a
DFT243	9/21/15	Barclays analyst report re CC "Refreshing Numbers"	n/a	n/a
DFT244	9/28/15	Jefferies analyst report re CC "TiO2 Pressures Continue"	n/a	n/a
DFT245	10/5/15	UBS analyst report re CC "New Presentation Highlights Cost Data; PT Updated"	n/a	n/a
DFT246	10/8/15	SIG Susquehanna, analyst report re CC "Chemours - Why the \$1.6M verdict x 3,500 cases DOES NOT EQUAL \$5.6 Billion"	n/a	n/a
DFT247	11/5/15	UBS analyst report re CC "No change to outlook; 3Q15 results lagged"	n/a	n/a
DFT248	11/6/15	Jefferies analyst report re CC "TiO2 Headwinds Blunt Productivity Near-Term. Efforts Likely Ratchet Up"	n/a	n/a
DFT249	11/6/15	Barclays analyst report re CC "Level-setting Expectations"	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT250	11/6/15	UBS, "Iluka Resources Limited, Tronox & Chemours conference call feedback"	n/a	n/a
DFT251	11/6/15	JP Morgan analyst report re CC "Starting Slowly"	n/a	n/a
DFT252	11/9/15	SIG Susquehanna analyst report re CC "Mounting Litigation"	n/a	n/a
DFT253	11/9/15	UBS analyst report re CC "Good Early Restructuring Progress in a Difficult Market"	n/a	n/a
DFT254	12/17/15	Jefferies analyst report re CC "End Markets Continue to Soften"	n/a	n/a
DFT255	12/17/15	Barclays analyst report re CC "CC Cutting Estimates (Fy'16 EBITDA goes from \$835m to \$725m)"	n/a	n/a
DFT256	12/18/15	SIG Susquehanna analyst report re CC "Cutting Estimates; Q1 Price Increase Announced"	n/a	n/a
DFT257	12/22/15	JP Morgan analyst report re CC "Model Update"	n/a	n/a
DFT258	2/5/16	Goldman Sachs analyst report re CC "Second bellweather PFOA case settles; updated 2017 case schedule"	NJ-CHE-FT2-156678	NJ-CHE-FT2-156685
DFT259	2/15/16	JP Morgan analyst report re CC "We Lower Estimates"	n/a	n/a
DFT260	2/25/16	Barclays analyst report re CC "Trough Fundamentals; Improved Liquidity"	n/a	n/a
DFT261	2/29/16	SIG Susquehanna analyst report re CC "Pricing Power Remains Challenged; Maintain Neutral Rating"	n/a	n/a
DFT262	4/8/16	S&P Ratings, "Chemours Co. Downgraded to 'BB-'; Outlook Stable; Debt Ratings Also Lowered"	n/a	n/a
DFT263	9/00/15	TZMI Ti02 Market Insight Issue 18, September 2015	AFFF-MDL-EID-FT-00090148	AFFF-MDL-EID-FT-00090181
DFT264	11/10/92	Benefit-Cost Analysis of Federal Programs; Guidelines and Discounts. Circular No. A-94, Revised Transmittal Memorandum No.	n/a	n/a
DFT265	9/17/03	Regulatory Analysis, Circular No. A-4 (2003)	n/a	n/a
DFT266	11/9/23	Regulatory Analysis, Circular No. A-4 (2023)	n/a	n/a
DFT267	11/9/23	Guidelines and Discount Rates for Benefit-Cost Analysis of Federal Programs, Circular No. A-94	n/a	n/a
DFT268	6/26/14	ASC Goodwill Step One Impairment Test for DTT	AFFF-MDL-EID-FT-00222635	AFFF-MDL-EID-FT-00222635
DFT269	12/11/14	E. I. du Pont de Nemours and Company, Chemours spin financing execution discussion materials presentation	AFFF-MDL-EID-FT-00017444	AFFF-MDL-EID-FT-00017519



<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT270	5/12/15	Chemours Deby underwriting commitments committee submission	JPM-AFFF-00007204	JPM-AFFF-00007269
DFT271	5/26/15	Memo to Office of the Chief Executive from Vergnano et al re Performance Chemicals Restructuring - Project SIM	AFFF-MDL-HLokey0034694	AFFF-MDL-HLokey0034712
DFT272	7/29/15	S&P Global Huntsman Corporation NYSE:HUM FQ2 2015 Earnings Call Transcripts	n/a	n/a
DFT273	10/27/15	S&P Global Huntsman Corporation NYSE:HUM FQ3 2015 Earnings Call Transcripts	n/a	n/a
DFT274	2/1/17	Email from Clayton to Hintlian attaching Realizability of Chemours Indemnifications Q4 16 memo	AFFF-MDL-EID-FT-00092859	AFFF-MDL-EID-FT-00092865
DFT275	9/18/17	Email from Clayton to Brown, Hopper attaching Realizability of Chemours Indemnifications August 2017 memo	AFFF-MDL-EID-FT-00092919	AFFF-MDL-EID-FT-00092997
DFT276	8/00/14	Chemical Solutions 2014 Strategy Review presentaion	JPM-AFFF-00000694	JPM-AFFF-00000759
DFT277	4/19/05	S.852 - Fairness in Asbestos Injury Resolution Act of 2005	n/a	n/a
DFT278	6/1/07	VS Section 100 - Statements on Standards for Valuation Services from the American Institute of Certified Public Accountants	n/a	n/a
DFT279	12/1/08	A. Damodaran article "What is the riskfree rate? A search for the basic building block"	n/a	n/a
DFT280	11/1/09	US DOJ Bureau of Justice Statistics Bulletin "Tort Bench and Jury Trials in State Courts, 2005"	DT00009707	DT00009727
DFT281	1/1/10	Yuan - Kidney Cancer Mortality Fifty-year Latency Patterns Related to Arsenic Exposure	n/a	n/a
DFT282	11/4/14	Email from Gilford to Parikh attaching Executed Leach Settlement Agreement	DT00000699	DT00000742
DFT283	1/2/15	Pepperdine University, Pepperdine Capital Markets Report, C. Everett, 2015 Private Capital Markets Report	n/a	n/a
DFT284	5/1/17	Wiley Finance Series, J. Hitchner "Financial Valuation; Application and Models" 4th Ed.	n/a	n/a
DFT285	1/1/05	RAND Institute for Civil Justice, "Asbestos Litigation"	n/a	n/a
DFT286	12/3/07	Mealey's Litigation Report, Asbestos, "Show Me the Money" by C. Bates and C. Mullin	n/a	n/a
DFT287	12/31/95	Pacific Gas and Electric Company, Form 10-K (1995)	n/a	n/a
DFT288	12/31/96	PG&E Corporation, Form 10-K (1996)	n/a	n/a
DFT289	12/31/00	PG&E Corporation, Form 10-K (2000)	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT290	12/31/02	PG&E Corporation, Form 10-K (2002)	n/a	n/a
DFT291	12/31/06	PG&E Corporation, Form 10-K (2006)	n/a	n/a
DFT292	12/4/07	Dorothy Adams et al v. Pacific Gas & Electric Co; 2007 Jury Verdicts LEXIS 37280	n/a	n/a
DFT293	12/31/07	PG&E Corporation, Form 10-K (2007)	n/a	n/a
DFT294	10/8/99	Wall Street Journal, "American Home Products Agrees to Pay Up to \$3.75 Billion in Diet-Drug Lawsuits"	n/a	n/a
DFT295	6/19/13	WTC Health Program Instructions for Completing WTC-3	n/a	n/a
DFT296	4/8/15	VCF Program Statistics as of 3-31-15	n/a	n/a
DFT297	7/20/15	VCF Program Statistics as of 6-30-15	n/a	n/a
DFT298	10/3/18	September 11th Victim Compensation Fund Compensation of Claims, 83 FR 49946-01	n/a	n/a
DFT299	1/1/23	September 11th Victim Compensation Fund VCF	n/a	n/a
DFT300	3/1/24	U.S. Department of Justice September 11th Victim Compensation Fund 2025 Budget and Performance Plan	n/a	n/a
DFT301	5/9/24	September 11th Victim Compensation Fund, Section 1: Eligibility Criteria and Deadlines	n/a	n/a
DFT302	7/1/24	WTC Health Program, Understanding Different 9-11 Assistance Programs	n/a	n/a
DFT303	4/28/15	NYTimes, "Takeda Agrees to Pay \$2.4 Billion to Settle Suits Over Cancer Risk of Actos"	n/a	n/a
DFT304	4/28/15	Lieff Cabraser, "Actos Bladder Cancer Lawsuits and Settlement"	n/a	n/a
DFT305	1/1/12	Manville Trust 2002 Distribution Process	DT00009921	DT00009960
DFT306	8/30/05	In re Prempro Class Cert Decision, MDL 4:04-CV-1507-WRW	n/a	n/a
DFT307	6/19/12	Bloomberg, "Pfizer paid \$896 Million in Prempro Settlements"	DT00006695	DT00006698
DFT308	4/18/14	ACS, "Cancer Compensation Programs for People Exposed to Radiation as Part of Nuclear Weapons Testing"	DT00006665	DT00006668
DFT309	3/2/15	U.S. Department of Justice Radiation Exposure Compensation Act	n/a	n/a
DFT310	1/1/04	A. Dittmart journal article "Capital Structure in Corporate Spin-Offs"	n/a	n/a
DFT311	1/1/15	Email attaching Wachtell, Lipton, Rosen & Katz - Spin-Off Guide	AFFF-MDL-EID-FT-00215300	AFFF-MDL-EID-FT-00215371
DFT312	1/27/15	Q4 2014 DuPont Earnings Conference Call Transcript	n/a	n/a
DFT313	7/28/15	Q2 2015 DuPont Earnings Conference Call Transcript	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT314	1/1/18	KPMG article "Can your valuation be improved?"	n/a	n/a
DFT315	1/1/22	KPMG article "The big breakup: the math behind giant divestitures"	n/a	n/a
DFT316	1/1/22	E. R. Feldman book "Divestitures: Creating Value Through Strategy, Structure, and Implementation"	n/a	n/a
DFT317	8/14/06	In re Armstrong World Industries, 348 B.R.111 (D. Del. August 14, 2006)	n/a	n/a
DFT318	12/12/13	In re Tronox Inc., 503 B.R. 239 (S.D.N.Y. 2013)	n/a	n/a
DFT319	9/3/14	Class notice re C-8	n/a	n/a
DFT320	1/1/24	ASC 450-20-55	n/a	n/a
DFT321	3/16/24	Value & Cents article "Mass Torts Gap in Contingent-Liability Valuation Guidance" by Hinton and Huffman	NC-FW-02707789	NC-FW-02707791
DFT322	5/1/24	American Cancer Society "Kidney Cancer Causes, Risk Factors, and Prevention"	n/a	n/a
DFT323	5/1/24	ACS Cancer.org Kidney Cancer Causes	n/a	n/a
DFT324	5/1/24	ACS Cancer.org Testicular Cancer Causes	n/a	n/a
DFT325	00/00/10	DuPont GenX Processing Aid for Making Fluoropolymer Resins	Carey-CHEM-00961032	Carey-CHEM-00961035
DFT326	8/6/15	The Chemours Company Q2 2015 Earnings Call Transcripts Aug 06 2015	n/a	n/a
DFT327	3/7/23	American Water Works Association. WITAF 56 technical memorandum, PFAS National Cost Model Report, B&V Project No. 409850	n/a	n/a
DFT328	00/00/00	Standard Guide for Estimating Monetary Costs and Liabilities for Environmental Matters	n/a	n/a
DFT329	00/00/00	PwC Financial Statement Presentation Guide 23.4	n/a	n/a
DFT330	00/00/09	Damodaran, Aswath, The Dark Side of Valuation: Valuing Young, Distressed, and Complex Businesses, 2009, Ch. 3	n/a	n/a
DFT331	00/00/14	Pratt, Shannon P., and Roger J. Grabowski, Cost of Capital: Applications and Examples, John Wiley & Sons, Incorporated, 2014, Ch. 6	n/a	n/a
DFT332	2005-2022	FASB 410 Asset Retirement and Environmental Obligations	n/a	n/a
DFT333	7/00/05	Sullivan, Edward. Estimating Environmental Liabilities	n/a	n/a
DFT334	00/00/00	Chandler, A and Salsbury, S, Pierre S. Du Pont and the Making of the Modern Corporation, 2000	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT335	00/00/02	Kinnane, Adrian, DuPont: From the Banks of the Brandywine to Miracles of Science, 2002	n/a	n/a
DFT336	8/6/15	Email from Giannantonio to Schaible and Vaske re Dow Merger Assessment	AFFF-MDL-EID-FT-00092061	AFFF-MDL-EID-FT-00092061
DFT337	8/29/15	Email from Giannantonio to Grier re Background on Project Hoops attaching analysis charts	AFFF-MDL-EID-FT-00030716	AFFF-MDL-EID-FT-00030785
DFT338	3/3/18	Email from Tauro to Giannantonio re Evercore - Spin Planning Materials attaching deck on Corteva separation	AFFF-MDL-EID-FT-00092310	AFFF-MDL-EID-FT-00092408
DFT339	5/6/19	DowDuPont Inc. BOD Minutes	AFFF-MDL-EID-FT-00210345	AFFF-MDL-EID-FT-00210485
DFT340	6/26/15	Chemours SA and Schedules and Exhibits	NJ-CTVA-00001457	NJ-CTVA-00004187
DFT341	12/11/15	DDP Agreement and Plan of Merger	AFFF-MDL-EID-FT-00091906	AFFF-MDL-EID-FT-00092006
DFT342	3/31/17	Am No 1 to DDP Agreement	AFFF-MDL-EID-FT-00122557	AFFF-MDL-EID-FT-00122564
DFT343	4/1/19	Schedules to SDA	NJ-CTVA-00000302	NJ-CTVA-00001294
DFT344	4/1/19	SDA and Exhibits	NJ-CTVA-00000001	NJ-CTVA-00000301
DFT345	6/1/19	Side Letter	NJ-CTVA-00001346	NJ-CTVA-00001456
DFT346	1/22/21	Memorandum of Understanding	n/a	n/a
DFT347	9/25/23	MOU Amendment (Executed)	AFFF-MDL-EID-FT-00221545	AFFF-MDL-EID-FT-00221546
DFT348	3/31/13	2013 Q1 - EIDP 10-Q	n/a	n/a
DFT349	6/30/13	2013 Q2 - EIDP 10-Q	n/a	n/a
DFT350	9/30/13	2013 Q3 - EIDP 10-Q	n/a	n/a
DFT351	10/25/13	EIDP 8-K	n/a	n/a
DFT352	11/6/13	EIDP 8-K	n/a	n/a
DFT353	12/31/13	2013 10-K EIDP	n/a	n/a
DFT354	3/31/14	2014 Q1 - EIDP 10-Q	n/a	n/a
DFT355	6/26/14	EIDP 8-K	n/a	n/a
DFT356	6/30/14	2014 Q2 - EIDP 10-Q	n/a	n/a
DFT357	9/30/14	2014 Q3 - EIDP 10-Q	n/a	n/a
DFT358	10/28/14	EIDP 8-K	n/a	n/a
DFT359	12/18/14	Chemours Company 10-12B	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT360	12/18/14	EIDP 8-K	n/a	n/a
DFT361	12/18/14	EIDP 8-K_A	n/a	n/a
DFT362	12/31/14	2014 10-K EIDP	n/a	n/a
DFT363	2/12/15	Chemours Company 10-12B_A	n/a	n/a
DFT364	3/13/15	Chemours Company 10-12B_A	n/a	n/a
DFT365	3/30/15	EIDP 8-K	n/a	n/a
DFT366	3/31/15	2015 Q1 - EIDP 10-Q	n/a	n/a
DFT367	4/21/15	Chemours Company 10-12B_A	n/a	n/a
DFT368	4/23/15	EIDP 8-K	n/a	n/a
DFT369	5/12/15	EIDP 8-K	n/a	n/a
DFT370	5/13/15	EIDP 8-K	n/a	n/a
DFT371	5/19/15	EIDP 8-K	n/a	n/a
DFT372	6/2/15	EIDP 8-K_A	n/a	n/a
DFT373	6/5/15	Chemours Company 10-12B_A	n/a	n/a
DFT374	6/5/15	Corteva 8-K (press release)	n/a	n/a
DFT375	6/9/15	EIDP 8-K_A	n/a	n/a
DFT376	6/18/15	Chemours Company 8-K	n/a	n/a
DFT377	6/19/15	Chemours Company 8-K	n/a	n/a
DFT378	6/30/15	Chemours Company - Form 10-Q (2015 Q2)	n/a	n/a
DFT379	6/30/15	2015 Q2 - EIDP 10-Q	n/a	n/a
DFT380	7/1/15	Chemours Company 8-K	n/a	n/a
DFT381	7/8/15	EIDP 8-K	n/a	n/a
DFT382	7/28/15	Chemours Company 8-K	n/a	n/a
DFT383	8/6/15	Chemours Company 8-K	n/a	n/a
DFT384	8/18/15	Chemours Company 8-K	n/a	n/a
DFT385	9/1/15	Chemours Company 8-K	n/a	n/a
DFT386	9/25/15	Chemours Company 8-K	n/a	n/a
DFT387	9/30/15	Chemours Company - Form 10-Q (2015 Q3)	n/a	n/a
DFT388	9/30/15	2015 Q3 - EIDP 10-Q	n/a	n/a
DFT389	10/15/15	EIDP 8-K	n/a	n/a
DFT390	11/5/15	Chemours Company 8-K	n/a	n/a
DFT391	11/12/15	Chemours Company 8-K	n/a	n/a
DFT392	11/19/15	Chemours Company 8-K	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT393	11/30/15	Chemours Company 8-K (investor presentation)	n/a	n/a
DFT394	11/30/15	Chemours Company 8-K (press release)	n/a	n/a
DFT395	12/11/15	EIDP 8-K (2)	n/a	n/a
DFT396	12/11/15	EIDP 8-K	n/a	n/a
DFT397	12/15/15	EIDP 8-K_A	n/a	n/a
DFT398	12/17/15	Chemours Company 8-K	n/a	n/a
DFT399	12/31/15	Chemours Company - Form 10-K (2015)	n/a	n/a
DFT400	12/31/15	2015 10-K EIDP	n/a	n/a
DFT401	2/23/16	Chemours Company 8-K (credit agreement)	n/a	n/a
DFT402	2/23/16	Chemours Company 8-K (press release)	n/a	n/a
DFT403	3/1/16	DowDuPont Form S-4	n/a	n/a
DFT404	3/31/16	Chemours Company - Form 10-Q (2016 Q1)	n/a	n/a
DFT405	3/31/16	2016 Q1 - EIDP 10-Q	n/a	n/a
DFT406	5/2/16	Chemours Company 8-K	n/a	n/a
DFT407	4/18/16	DowDuPont Form S-4_A	n/a	n/a
DFT408	4/25/16	Chemours Company 8-K	n/a	n/a
DFT409	5/23/16	DowDuPont Form S-4_A	n/a	n/a
DFT410	6/2/16	Chemours Company 8-K	n/a	n/a
DFT411	6/7/16	DowDuPont Form S-4_A	n/a	n/a
DFT412	6/8/16	Chemours Company 8-K (investor presentation)	n/a	n/a
DFT413	6/8/16	Chemours Company 8-K (statement)	n/a	n/a
DFT414	6/10/16	DownDuPont Form 424(b)(3)	n/a	n/a
DFT415	6/14/16	Chemours Company 8-K	n/a	n/a
DFT416	6/30/16	Chemours Company - Form 10-Q (2016 Q2)	n/a	n/a
DFT417	6/30/16	2016 Q2 - EIDP 10-Q	n/a	n/a
DFT418	7/6/16	Chemours Company 8-K	n/a	n/a
DFT419	7/8/16	Chemours Company 8-K	n/a	n/a
DFT420	7/8/16	EIDP 8-K	n/a	n/a
DFT421	8/8/16	Chemours Company 8-K	n/a	n/a
DFT422	9/14/16	Chemours Company 8-K	n/a	n/a
DFT423	9/30/16	Chemours Company - Form 10-Q (2016 Q3)	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT424	9/30/16	2016 Q3 - EIDP 10-Q	n/a	n/a
DFT425	11/6/15	EIDP 8-K	n/a	n/a
DFT426	11/6/16	Chemours Company 8-K	n/a	n/a
DFT427	11/28/18	DowDuPont 8-K	n/a	n/a
DFT428	12/31/16	Chemours Company - Form 10-K (2016)	n/a	n/a
DFT429	12/31/16	2016 10-K (E.I. DuPont De Nemours and Company)	n/a	n/a
DFT430	2/13/17	EIDP 8-K	n/a	n/a
DFT431	3/31/17	Chemours Company - Form 10-Q (2017 Q1)	n/a	n/a
DFT432	3/31/17	2017 Q1 - EIDP 10-Q	n/a	n/a
DFT433	6/30/17	Chemours Company - Form 10-Q (2017 Q2)	n/a	n/a
DFT434	6/30/17	2017 Q2 - EIDP 10-Q	n/a	n/a
DFT435	8/4/17	EIDP 8-K	n/a	n/a
DFT436	8/25/17	EIDP 8-K	n/a	n/a
DFT437	9/1/17	DowDuPont 8-K12B	n/a	n/a
DFT438	9/1/17	EIDP 8-K	n/a	n/a
DFT439	9/12/17	DowDuPont 8-K	n/a	n/a
DFT440	9/30/17	Chemours Company - Form 10-Q (2017 Q3)	n/a	n/a
DFT441	9/30/17	DuPont de Nemours - Form 10-Q (2017 Q3)	n/a	n/a
DFT442	9/30/17	2017 Q3 - EIDP 10-Q	n/a	n/a
DFT443	10/26/17	DowDuPont 8-K (2)	n/a	n/a
DFT444	10/26/17	DowDuPont 8-K	n/a	n/a
DFT445	10/26/17	DowDuPont 8-K_A	n/a	n/a
DFT446	11/2/17	DowDuPont 8-K (2)	n/a	n/a
DFT447	11/2/17	DowDuPont 8-K	n/a	n/a
DFT448	11/2/17	EIDP 8-K	n/a	n/a
DFT449	12/31/17	Chemours Company - Form 10-K (2017)	n/a	n/a
DFT450	12/31/17	DuPont de Nemours - Form 10-K (2017) (DowDuPont)	n/a	n/a
DFT451	12/31/17	2017 10-K (E.I. DuPont De Nemours and Company)	n/a	n/a
DFT452	10/18/18	Corteva 10-12B	n/a	n/a
DFT453	2/1/18	DowDuPont 8-K	n/a	n/a
DFT454	3/31/18	Chemours Company - Form 10-Q (2018 Q1)	n/a	n/a
DFT455	3/31/18	Dow Chemical Company - Form 10-Q (2018 Q1)	n/a	n/a
DFT456	3/31/18	DuPont de Nemours - Form 10-Q (2018 Q1)	n/a	n/a



<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT457	3/31/18	2018 Q1 - EIDP 10-Q	n/a	n/a
DFT458	5/3/18	DowDuPont 8-K	n/a	n/a
DFT459	6/30/18	Chemours Company - Form 10-Q (2018 Q2)	n/a	n/a
DFT460	6/30/18	Dow Chemical Company - Form 10-Q (2018 Q2)	n/a	n/a
DFT461	6/30/18	2018 Q2 - EIDP 10-Q	n/a	n/a
DFT462	9/6/18	DowDuPont 8-K	n/a	n/a
DFT463	9/7/18	Form 10-12B (Dow Holdings)	n/a	n/a
DFT464	9/30/18	Chemours Company - Form 10-Q (2018 Q3)	n/a	n/a
DFT465	9/30/18	Dow Chemical Company - Form 10-Q (2018 Q3)	n/a	n/a
DFT466	9/30/18	2018 Q3 - EIDP 10-Q	n/a	n/a
DFT467	10/18/18	DowDuPont 8-K	n/a	n/a
DFT468	10/18/18	EIDP 8-K	n/a	n/a
DFT469	10/19/18	Form 10-12B_A (Dow Holdings)	n/a	n/a
DFT470	11/1/18	DowDuPont 8-K	n/a	n/a
DFT471	11/13/18	DowDuPont 424B5	n/a	n/a
DFT472	11/16/18	DowDuPont 424B2	n/a	n/a
DFT473	11/19/18	Form 10-12B_A (Dow Holdings)	n/a	n/a
DFT474	12/19/18	Corteva 10-12B_A	n/a	n/a
DFT475	12/31/18	Chemours Company - Form 10-K (2018)	n/a	n/a
DFT476	12/31/18	Dow Chemical Company - Form 10-K (2018)	n/a	n/a
DFT477	12/31/18	DuPont de Nemours - Form 10-K (2018) (DowDuPont)	n/a	n/a
DFT478	12/31/18	2018 10-K (E.I. DuPont De Nemours and Company)	n/a	n/a
DFT479	1/31/19	DowDuPont 8-K	n/a	n/a
DFT480	2/11/19	Form 10-12B_A (Dow Holdings)	n/a	n/a
DFT481	3/8/19	Form 10-12B_A (Dow Inc)	n/a	n/a
DFT482	3/19/19	Corteva 10-12B_A	n/a	n/a
DFT483	3/31/19	Chemours Company - Form 10-Q (2019 Q1)	n/a	n/a
DFT484	3/31/19	Corteva - Form 10-Q (2019 Q1)	n/a	n/a
DFT485	3/31/19	Dow Inc - Form 10-Q (2019 Q1)	n/a	n/a
DFT486	3/31/19	DuPont de Nemours - Form 10-Q (2019 Q1)	n/a	n/a
DFT487	3/31/19	2019 Q1 - EIDP 10-Q	n/a	n/a
DFT488	4/2/19	DowDuPont 8-K	n/a	n/a
DFT489	4/15/19	Corteva 10-12B_A	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT490	5/2/19	DowDuPont 8-K	n/a	n/a
DFT491	5/3/19	EIDP 8-K	n/a	n/a
DFT492	5/6/19	Corteva 10-12B_A	n/a	n/a
DFT493	5/9/19	Corteva 8-K	n/a	n/a
DFT494	5/23/19	DowDuPont 8-K	n/a	n/a
DFT495	5/29/19	DowDuPont 8-K	n/a	n/a
DFT496	5/31/19	Corteva 424(b)(5)	n/a	n/a
DFT497	5/31/19	Corteva 8-K (financials)	n/a	n/a
DFT498	5/31/19	Corteva 8-K (prospectus supplement)	n/a	n/a
DFT499	6/3/19	Corteva 8-K	n/a	n/a
DFT500	6/3/19	DuPont de Nemours 8-K	n/a	n/a
DFT501	6/3/19	EIDP 8-K	n/a	n/a
DFT502	6/7/19	DuPont de Nemours 8-K	n/a	n/a
DFT503	6/26/19	Corteva 8-K	n/a	n/a
DFT504	6/30/19	Chemours Company - Form 10-Q (2019 Q2)	n/a	n/a
DFT505	6/30/19	Corteva - Form 10-Q (2019 Q2)	n/a	n/a
DFT506	6/30/19	Dow Inc - Form 10-Q (2019 Q2)	n/a	n/a
DFT507	6/30/18	DuPont de Nemours - Form 10-Q (2018 Q2)	n/a	n/a
DFT508	6/30/19	DuPont de Nemours - Form 10-Q (2019 Q2)	n/a	n/a
DFT509	8/1/19	Corteva 8-K 9 (regulation FD disclosure)	n/a	n/a
DFT510	8/1/19	DuPont de Nemours 8-K	n/a	n/a
DFT511	8/15/19	Corteva 8-K	n/a	n/a
DFT512	9/30/19	Chemours Company - Form 10-Q (2019 Q3)	n/a	n/a
DFT513	9/30/19	Corteva - Form 10-Q (2019 Q3)	n/a	n/a
DFT514	9/30/19	Dow Inc - Form 10-Q (2019 Q3)	n/a	n/a
DFT515	9/30/18	DuPont de Nemours - Form 10-Q (2018 Q3)	n/a	n/a
DFT516	9/30/19	DuPont de Nemours - Form 10-Q (2019 Q3)	n/a	n/a
DFT517	10/31/19	Corteva 8-K	n/a	n/a
DFT518	10/31/19	DuPont de Nemours 8-K	n/a	n/a
DFT519	12/31/19	Chemours Company - Form 10-K (2019)	n/a	n/a
DFT520	12/31/19	Corteva - Form 10-K (2019)	n/a	n/a
DFT521	12/31/19	Dow Inc - Form 10-K (2019)	n/a	n/a
DFT522	12/31/19	DuPont de Nemours - Form 10-K (2019)	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT523	12/31/19	2019 10-K (E.I. DuPont De Nemours and Company)	n/a	n/a
DFT524	1/30/20	Corteva 8-K	n/a	n/a
DFT525	2/18/20	Corteva 8-K	n/a	n/a
DFT526	2/21/20	Corteva 8-K	n/a	n/a
DFT527	3/31/20	Chemours Company - Form 10-Q (2020 Q1)	n/a	n/a
DFT528	3/31/20	Corteva - Form 10-Q (2020 Q1)	n/a	n/a
DFT529	3/31/20	Dow Inc - Form 10-Q (2020 Q1)	n/a	n/a
DFT530	3/31/20	DuPont de Nemours - Form 10-Q (2020 Q1)	n/a	n/a
DFT531	5/6/20	Corteva 8-K	n/a	n/a
DFT532	6/30/20	Chemours Company - Form 10-Q (2020 Q2)	n/a	n/a
DFT533	6/30/20	Corteva - Form 10-Q (2020 Q2)	n/a	n/a
DFT534	6/30/20	Dow Inc - Form 10-Q (2020 Q2)	n/a	n/a
DFT535	6/30/20	DuPont de Nemours - Form 10-Q (2020 Q2)	n/a	n/a
DFT536	8/5/20	Corteva 8-K	n/a	n/a
DFT537	9/30/20	Chemours Company - Form 10-Q (2020 Q3)	n/a	n/a
DFT538	9/30/20	Corteva - Form 10-Q (2020 Q3)	n/a	n/a
DFT539	9/30/20	Dow Inc - Form 10-Q (2020 Q3)	n/a	n/a
DFT540	9/30/20	DuPont de Nemours - Form 10-Q (2020 Q3)	n/a	n/a
DFT541	11/4/20	Corteva 8-K	n/a	n/a
DFT542	12/31/20	Chemours Company - Form 10-K (2020)	n/a	n/a
DFT543	12/31/20	Corteva - Form 10-K (2020)	n/a	n/a
DFT544	12/31/20	Dow Inc - Form 10-K (2020)	n/a	n/a
DFT545	12/31/20	DuPont de Nemours - Form 10-K (2020)	n/a	n/a
DFT546	3/31/21	Chemours Company - Form 10-Q (2021 Q1)	n/a	n/a
DFT547	3/31/21	Corteva - Form 10-Q (2021 Q1)	n/a	n/a
DFT548	3/31/21	DuPont de Nemours - Form 10-Q (2021 Q1)	n/a	n/a
DFT549	9/30/21	Chemours Company - Form 10-Q (2021 Q2)	n/a	n/a
DFT550	6/30/21	Corteva - Form 10-Q (2021 Q2)	n/a	n/a
DFT551	6/30/21	DuPont de Nemours - Form 10-Q (2021 Q2)	n/a	n/a
DFT552	9/30/21	Chemours Company - Form 10-Q (2021 Q3)	n/a	n/a
DFT553	9/30/21	Corteva - Form 10-Q (2021 Q3)	n/a	n/a
DFT554	9/30/21	DuPont de Nemours - Form 10-Q (2021 Q3)	n/a	n/a
DFT555	12/31/21	Chemours Company - Form 10-K (2021)	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT556	12/31/21	Corteva - Form 10-K (2021)	n/a	n/a
DFT557	12/31/21	DuPont de Nemours - Form 10-K (2021)	n/a	n/a
DFT558	3/31/22	Chemours Company - Form 10-Q (2022 Q1)	n/a	n/a
DFT559	3/31/22	Corteva - Form 10-Q (2022 Q1)	n/a	n/a
DFT560	3/31/22	DuPont de Nemours - Form 10-Q (2022 Q1)	n/a	n/a
DFT561	6/30/22	Chemours Company - Form 10-Q (2022 Q2)	n/a	n/a
DFT562	6/30/22	Corteva - Form 10-Q (2022 Q2) (2)	n/a	n/a
DFT563	6/30/22	DuPont de Nemours - Form 10-Q (2022 Q2)	n/a	n/a
DFT564	6/30/22	Corteva - Form 10-Q (2022 Q2)	n/a	n/a
DFT565	9/30/22	DuPont de Nemours - Form 10-Q (2022 Q3)	n/a	n/a
DFT566	12/31/22	Chemours Company - Form 10-K (2022)	n/a	n/a
DFT567	12/31/22	Corteva - Form 10-K (2022)	n/a	n/a
DFT568	12/31/22	DuPont de Nemours - Form 10-K (2022)	n/a	n/a
DFT569	3/31/23	Chemours Company - Form 10-Q (2023 Q1)	n/a	n/a
DFT570	3/31/23	Corteva - Form 10-Q (2023 Q1)	n/a	n/a
DFT571	3/31/23	DuPont de Nemours - Form 10-Q (2023 Q1)	n/a	n/a
DFT572	6/30/23	Chemours Company - Form 10-Q (2023 Q2)	n/a	n/a
DFT573	6/30/23	Corteva - Form 10-Q (2023 Q2)	n/a	n/a
DFT574	6/30/23	DuPont de Nemours - Form 10-Q (2023 Q2)	n/a	n/a
DFT575	9/30/23	Chemours Company - Form 10-Q (2023 Q3)	n/a	n/a
DFT576	9/30/23	Corteva - Form 10-Q (2023 Q3)	n/a	n/a
DFT577	9/30/23	DuPont de Nemours - Form 10-Q (2023 Q3)	n/a	n/a
DFT578	12/31/23	Chemours Company - Form 10-K (2023)	n/a	n/a
DFT579	12/31/23	Corteva - Form 10-K (2023)	n/a	n/a
DFT580	12/31/23	DuPont de Nemours - Form 10-K (2023)	n/a	n/a
DFT581	3/31/24	Chemours Company - Form 10-Q (2024 Q1)	n/a	n/a
DFT582	3/31/24	Corteva - Form 10-Q (2024 Q1)	n/a	n/a
DFT583	3/31/24	DuPont de Nemours - Form 10-Q (2024 Q1)	n/a	n/a
DFT584	6/30/24	Chemours Company - Form 10-Q (2024 Q2)	n/a	n/a
DFT585	6/30/24	Corteva - Form 10-Q (2024 Q2)	n/a	n/a
DFT586	6/30/24	DuPont de Nemours - Form 10-Q (2024 Q2)	n/a	n/a
DFT587	9/30/24	Chemours Company - Form 10-Q (2024 Q3)	n/a	n/a
DFT588	9/30/24	Corteva - Form 10-Q (2024 Q3)	n/a	n/a

<b>Trial Exhibit No.</b>	<b>Document Date</b>	<b>Description</b>	<b>BegBates</b>	<b>EndBates</b>
DFT589	9/30/24	DuPont de Nemours - Form 10-Q (2024 Q3)	n/a	n/a
DFT590	12/31/24	Chemours Company - Form 10-K (2024)	n/a	n/a
DFT591	12/31/24	Corteva - Form 10-K (2024)	n/a	n/a
DFT592	12/31/24	DuPont de Nemours - Form 10-K (2024)	n/a	n/a